Experienced antimicrobial drug discovery scientist and consultant with a long and successful record of working in the anti-infective discovery industry. Skilled in preclinical antimicrobial development (antibacterial, antifungal), including animal infection models from basic models through to PK/PD and assisting in program design from discovery through to IND submission.
Broad experience working with large Pharma, Biotech companies, virtual companies and academia focused on infectious diseases, both in the United States and overseas.
Whether your product is a small molecule, biologic, phage, vaccine, adjuvant or antibody, we can provide tailored assistance to help you plan and advance your preclinical program.
This includes expertise in:
William Weiss, Preclinical Consultant
845-238-9092
845-238-9092 /
Email /
LinkedIn
William Weiss
Preclinical Consultant
As Director of PreClinical Research Services (PCS) in the HSC College of Pharmacy, Bill directs a team of scientists that conducts industry sponsored research studies utilizing established models of both acute and chronic bacterial and fungal infections in multiple animal species including pharmacokinetic / pharmacodynamic studies with bioanalytical LCMS / HPLC analysis. Here he utilizes his experience to guide the drug discovery process, from protocol design to implementation and analysis for compound lead selection.
Before leading the PCS group, he was Director of Drug Evaluation at Cumbre Pharmaceuticals Inc. where he was responsible for animal efficacy models, pharmacology and all preclinical research and development efforts through IND submission focused on the discovery & development of new antimicrobial agents. Prior to this, he was a Group Leader in Infectious Disease Discovery Research at Wyeth Research (Pfizer), Lederle Laboratories and Schering-Plough (Merck), holding various positions of responsibility in antibacterial, antiviral and antifungal drug discovery research for over 43 years. His responsibilities included leading in vitro and in vivo evaluation of novel test articles from medicinal synthetic and natural products chemistry.
He has worked on numerous antibacterial programs including the development of the marketed antibiotics; Suprax, Zosyn, Tygacil, Plazomicin, Xerava, Cubicin, Vabomere and AvyCaz. His expertise encompasses the development of animal research models, evaluation of new and novel therapeutic agents (small molecules, biologics, vaccines, antibodies) as well as pharmacokinetic / pharmacodynamic analysis. He has authored / co-authored over 50 journal articles and over 100 research presentations.
